Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 22 OCTOBER 2026 ASX RELEASE AMPLIA RECEIVES R&D TAX REBATE TOTALLING $4.78 MILLION Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleasedto advise that ithas received A$4,778,235.52 via theResearchand Development Tax Incentive from the Australian Tax Office for the financial year ended 31 March 2026. The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with a tax offset of 43.5%-48.5% (refundable) for eligible expenditure on R&D activities. The refund relates to expenditure incurred in R&D activities associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886. These activities primarily related to the Company’s ongoing clinical trials of narmafotinib in advanced pancreatic cancer patients. The funds will contribute to the further progression of both the ACCENT and AMPLICITY clinical trials of narmafotinib along with the ACCENT-MINI Trial, the PRROSE Study, the Lilly combination studies and additional supporting R&D activities. This ASX announcement was approved and authorised for release by the Chair of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Media Contact: Hannah Howlett, Titch Comms Hannah@titchcomms.com.au +61 450 648 064 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over- expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported. A second trial – AMPLICITY – is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in first-line patients with advanced pancreatic cancer.